{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:40:57Z","timestamp":1792233657608,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.revmed.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:45:06Z","timestamp":1792230306000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extracardiovascular immune-related adverse events in patients with suspected cardiac toxicity associated with immune checkpoint inhibitors"],"prefix":"10.1016","author":[{"given":"Fran\u00e7ois","family":"Fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cribari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Henriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Hamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s Lillo","family":"Le Louet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Caussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Mirabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.revmed.2026.08.008_bib0005","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.revmed.2026.08.008_bib0010","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2026.08.008_bib0015","series-title":"Oncology (cancer)\/hematologic malignancies approval notifications [Internet]","year":"2024"},{"issue":"1","key":"10.1016\/j.revmed.2026.08.008_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.revmed.2026.08.008_bib0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.revmed.2026.08.008_bib0030","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-l1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.revmed.2026.08.008_bib0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00262-024-03734-1","article-title":"Efficacy and safety of anti-PD-1\/PD-L1-based dual immunotherapies versus PD-1\/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.revmed.2026.08.008_bib0040","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u202f\u2013\u202fa worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.revmed.2026.08.008_bib0045","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"230","key":"10.1016\/j.revmed.2026.08.008_bib0050","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.revmed.2026.08.008_bib0055","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"10.1016\/j.revmed.2026.08.008_bib0060","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.revmed.2026.08.008_bib0065","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.revmed.2026.08.008_bib0070","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","article-title":"Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study","volume":"47","author":"Salem","year":"2026","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.revmed.2026.08.008_bib0075","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.revmed.2026.08.008_bib0080","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.revmed.2026.08.008_bib0085","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1002\/cam4.2510","article-title":"The effects and safety of PD-1\/PD-L1 inhibitors on head and neck cancer: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.revmed.2026.08.008_bib0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.revmed.2026.08.008_bib0095","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.acvd.2025.06.073","article-title":"Cardiovascular safety of a standardized outpatient triage and diagnostic approach for suspected cardiovascular immune-related adverse events of immune checkpoint inhibitors","volume":"118","author":"Cribari","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.revmed.2026.08.008_bib0100","series-title":"Common terminology criteria for adverse events (CTCAE) [Internet]","year":"2024"},{"issue":"6","key":"10.1016\/j.revmed.2026.08.008_bib0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"14","key":"10.1016\/j.revmed.2026.08.008_bib0110","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3390\/ijms241411504","article-title":"Checkpoint inhibitor-induced colitis: from pathogenesis to management","volume":"24","author":"Terrin","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.revmed.2026.08.008_bib0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.acvd.2024.12.012","article-title":"Diagnosis of cancer therapy-related cardiovascular toxicities: a multimodality integrative approach and future developments","volume":"118","author":"Travers","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"issue":"13","key":"10.1016\/j.revmed.2026.08.008_bib0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310919","article-title":"Pembrolizumab-induced fatal myasthenia, myocarditis, and myositis in a patient with metastatic melanoma: autopsy, histological, and immunohistochemical findings\u202f\u2013\u202fa case report and literature review","volume":"24","author":"Giovannini","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.revmed.2026.08.008_bib0125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","article-title":"Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis","volume":"80","author":"Oliveira","year":"2024","journal-title":"Eur J Clin Pharmacol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326007010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326007010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:45:09Z","timestamp":1792230309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866326007010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"alternative-id":["S0248866326007010"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2026.08.008","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracardiovascular immune-related adverse events in patients with suspected cardiac toxicity associated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}